Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: October 26, 2023
Reporting Period: Third Quarter 2023
This filing serves as a notification that the Company issued an Earnings Press Release and a presentation regarding its financial results for the third quarter of 2023. The detailed financial data is contained within the exhibits incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are disclosed in the Earnings Press Release (Exhibit 99.1) and the Bristol Myers Presentation (Exhibit 99.2), which are referenced but not included in the body of this 8-K filing.
Material Changes
The filing text does not explicitly detail material changes versus the prior comparable period. It directs investors to the attached exhibits for the announcement of financial results and operating initiatives.
Guidance, Outlook, and Management Commentary
- Disclosure Method: Management commentary and financial outlook were provided during a conference call and webcast held on October 26, 2023, at 8:00 a.m. Eastern time.
- Non-GAAP Measures: The Earnings Press Release and Presentation include non-GAAP financial information. Reconciliations to GAAP measures are available in Exhibit 99.1.
- Availability: The presentation materials are available on the Company's website (www.bms.com) but may be discontinued at any time.
- Legal Status: Information in Item 7.01 (Regulation FD Disclosure) is not deemed "filed" under the Exchange Act and is not subject to Section 18 liabilities, nor is it incorporated by reference into future filings unless specifically stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q3 2023 revenue, net income, and earnings per share figures.
- Examine Exhibit 99.2 (Presentation Materials) for management's outlook, pipeline updates, and strategic initiatives.
- Verify the reconciliation between non-GAAP and GAAP financial measures provided in the press release.
- Confirm the status of the Celgene Contingent Value Rights (CELG RT) listed as a registered security.